Literature DB >> 10571628

Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer.

G Sanz1, J E Robles, M Giménez, J Arocena, D Sánchez, F Rodriguez-Rubio, D Rosell, J A Richter, J M Berián.   

Abstract

OBJECTIVE: To determine the role of the positron emission tomography (PET) with 18F-labelled deoxyglucose in the identification of prostatic cancer in the iliac and obturator lymphatic nodes before radical prostatectomy, and in the localization of relapse in patients in biochemical progression. PATIENTS AND METHODS: Twenty-one patients were divided into two groups. Group A consisted of 11 men diagnosed with organ-confined prostate cancer, where attention was focused on the iliac and obturator lymphatic nodes, the results being compared with the pathological anatomy obtained from surgical procedures. Group B included 10 patients treated by radical prostatectomy, radiotherapy or orchidectomy and who were in biochemical progression, in whom the aim was to identify recurrence of the disease.
RESULTS: In none of the 11 patients of group A who had undergone radical prostatectomy were deposits of radiotracer identified in the area of the iliac and obturator nodes which would indicate node metastases. However, the histopathological analysis of these nodes showed tumour in three patients. In group B the PET scans showed recurrence of prostate cancer (by deposits of radiotracer) more clearly than did computed tomography (CT) in two patients (both with recurrence in soft tissue). In one patient bone scintigraphy identified a lesion compatible with prostatic disease in the bone; this was clinically confirmed but was not identified by PET.
CONCLUSION: PET, using deoxyglucose labelled with 18F, cannot reliably identify prostatic adenocarcinoma in the iliac and obturator lymph nodes before surgery; other tracers may give better results. To locate relapses in patients with biochemical progression, PET seems to have better sensitivity than CT when identifying diseases in soft tissues and is possibly inferior to bone scintigraphy in detecting bony metastases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571628     DOI: 10.1046/j.1464-410x.1999.00349.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  FDG PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2009-04-01

Review 2.  [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].

Authors:  M P Wirth; F M Engelhardt
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

Review 3.  Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

Authors:  Reza Vali; Wolfgang Loidl; Christian Pirich; Werner Langesteger; Mohsen Beheshti
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-01-15

4.  Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy.

Authors:  Michael J Morris; Timothy Akhurst; Steven M Larson; Marisa Ditullio; Elaina Chu; Karen Siedlecki; David Verbel; Glenn Heller; W Kevin Kelly; Susan Slovin; Lawrence Schwartz; Howard I Scher
Journal:  Clin Cancer Res       Date:  2005-05-01       Impact factor: 12.531

Review 5.  Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU).

Authors:  Pasquale Martino; Vincenzo Scattoni; Andrea B Galosi; Paolo Consonni; Carlo Trombetta; Silvano Palazzo; Carmen Maccagnano; Giovanni Liguori; Massimo Valentino; Michele Battaglia; Libero Barozzi
Journal:  World J Urol       Date:  2011-05-08       Impact factor: 4.226

Review 6.  PET and prostate cancer.

Authors:  G Sanz; J Rioja; J J Zudaire; J M Berián; J A Richter
Journal:  World J Urol       Date:  2004-10-16       Impact factor: 4.226

Review 7.  Non-invasive molecular imaging of prostate cancer lymph node metastasis.

Authors:  Frédéric Pouliot; Mai Johnson; Lily Wu
Journal:  Trends Mol Med       Date:  2009-05-29       Impact factor: 11.951

Review 8.  Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.

Authors:  Hossein Jadvar
Journal:  Nat Rev Urol       Date:  2009-05-12       Impact factor: 14.432

Review 9.  Positron emission tomography (PET) in the urooncological evaluation of the small pelvis.

Authors:  S Machtens; J Serth; A Meyer; C Kleinhorst; K-J Ommer; U Herbst; M Kieruij; A R Boerner
Journal:  World J Urol       Date:  2007-07-12       Impact factor: 4.226

10.  Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment.

Authors:  José A Richter; Macarena Rodríguez; Jorge Rioja; Iván Peñuelas; Josep Martí-Climent; Puy Garrastachu; Gemma Quincoces; Javier Zudaire; María J García-Velloso
Journal:  Mol Imaging Biol       Date:  2009-06-19       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.